Association Between Plasma Levels of Monocyte Chemoattractant Protein-1 and Long-Term Clinical Outcomes in Patients With Acute Coronary Syndromes

Abstract

Background-Monocyte chemoattractant protein-1 (MCP-1) is a chemokine responsible for the recruitment of monocytes to sites of inflammation. MCP-1 appears to play a critical role at multiple stages in atherosclerosis, including the initiation of the fatty streak, promotion of plaque instability, and remodeling after myocardial infarction. After adjustment for differences in baseline characteristics, ECG changes, troponin I, and C-reactive protein, an MCP-1 level Ͼ75th percentile (corresponding to the 90th percentile in the healthy volunteers) was associated with an increased risk of death or myocardial infarction through 10 months of follow-up (adjusted hazard ratio, 1.53; 95% CI, 1.09 to 2.14; Pϭ0.01). Conclusions-In a large cohort of patients with acute coronary syndromes, an elevated baseline level of MCP-1 was associated both with traditional risk factors for atherosclerosis as well as an increased risk for death or myocardial infarction, independent of baseline variables. Because it appears to play a crucial role at multiple stages of atherosclerosis, MCP-1 is attractive as a surrogate biomarker and merits further study as a potential therapeutic target.

Association between the A?2518G polymorphism in the monocyte chemoattractant protein-1 gene and insulin resistance and Type 2 diabetes mellitus

“…Our findings of decreased plasma MCP-1 levels in carriers of the G allele are in agreement with data in patients with lupus nephritis [25]. In the present study, plasma MCP-1 levels were significantly and positively correlated with markers of the metabolic syndrome, such as insulin resistance, Type 2 diabetes, hypertension, obesity, WHR, high triglycerides and low HDL [36,37]. Conversely, another study showed that insulin infusion results in decreased plasma MCP-1 levels in obese subjects [38].…”

Protein Biomarkers of Cardiovascular Disease and Mortality in the Community

“…We report an association of SAA1 with all‐cause and CVD mortality. MCP1 is a chemokine that regulates monocyte trafficking and previously has been associated with myocardial infarction in FHS and adverse outcomes in patients with acute coronary syndrome 39, 40. sGP130 is a natural inhibitor of IL6 responses and has been associated with adverse outcomes among ischemic HF patients 41.…”

Circulating MCP-1 levels shows linkage to chemokine receptor gene cluster on chromosome 3: the NHLBI Family Heart Study follow-up examination

“…4 In human studies, serum levels of MCP-1 have been associated with older age, female sex, hypertension, diabetes, history of coronary disease, renal insufficiency, measures of adiposity and other inflammatory mediators including C-reactive protein (CRP), interleukin-6, interleukin-18, interleukin-8 and IP-10. [5][6][7] However, the relationship between levels of MCP-1 and risk of atherosclerotic diseases is inconsistent. Researchers using the Framingham Heart Study cohort reported that allele À2578G in the MCP-1 gene was significantly associated with increased serum levels of MCP-1 and a higher prevalence of myocardial infarction (MI).…”